Purpose / DescriptionThis trial was an open-label, phase 2b trial to evaluate the efficacy of a fixed-dose combination of sofosbuvir-velpatasvir-voxilaprevir for 12 weeks in adults with chronic HCV GT 1 infection and a history of virologic rebound following DAA therapy. With an intent-to-treat analysis, the overall SVR12 rate was 91% (70 of 77). Using a per protocol analysis, the SVR12 rate was 99% (70 of 71). Among the study participants with HIV, 82% (14 of 17) achieved an SVR12